Document is current
Any future updates will be listed below
-
Authors
Freedland, Stephen J.
Ramaswamy, Krishnan
Kavati, Abhishek
Gao, Wei
Razo, Juan F.
Cole, Michele
Li, Benjamin
Yang, Hongbo
Guo, Tracy
Chen, Grace
McKay, Rana R.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06462014 at ClinicalTrials.govDocuments that mention this clinical trial
Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration
https://doi.org/10.1007/s12325-025-03390-6
-
Funding
Funding for this research was provided by:
Pfizer Inc. in collaboration with Sumitomo Pharma Switzerland GmbH
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 25 September 2025
First Online: 1 November 2025
Declarations
:
: Stephen J. Freedland has served in a consulting or advisory role to the following companies: Pfizer, Astellas Pharma, Janssen, Sanofi, Myovant, Merck, AstraZeneca, Novartis, Eli Lilly, Tolmar, and Bayer. Krishnan Ramaswamy, Abhishek Kavati, Juan F. Razo, and Benjamin Li are employees of Pfizer Inc. and own stock/stock options. Michele Cole is an employee of Sumitomo Pharma America. Wei Gao, Hongbo Yang, Tracy Guo, and Grace Chen are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to the study sponsors for this work. Rana R. McKay has served in a consulting or advisory role to the following companies: Pfizer, Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, AstraZeneca, and Myovant.
: The study was considered exempt from institutional review board (IRB) review and informed consent under 45 CFR § 46.104(d)(4), as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR § 164.514.
